Author pages are created from data sourced from our academic publisher partnerships and public sources.
Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
- E. D. Saad, M. Machado, +6 authors R. Gansl
- International journal of gastrointestinal cancer
- 1 December 2002
SummaryBackground. Serum levels of CA 19-9 correlate with survival among patients with pancreatic cancer treated with surgery or radiation therapy. In addition, CA 19-9 responses have been shown to… Expand
Pretreatment level of CA 19-9 is a prognostic factor in advanced pancreatic cancer treated with chemotherapy
Critérios comuns de toxicidade do Instituto Nacional de Câncer dos Estados Unidos
Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients—An analysis from the Brazilian Hodgkin Lymphoma Registry
- I. Biasoli, Nelson Castro, +23 authors N. Spector
- International journal of cancer
- 1 March 2018
Socioeconomic status (SES) is a well‐known determinant of outcomes in cancer. The purpose of this study was to analyze the impact of the SES on the outcomes of Hodgkin lymphoma (HL) patients from the… Expand
Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry
Data about Hodgkin lymphoma (HL) in developing countries are scarce and suggest the existence of substantial disparities in healthcare and outcomes in large areas of the world. In 2009, a prospective… Expand
Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy.
- A. Katz, C. Barrios, R. Abramoff, S. Simon, J. Tabacof, R. Gansl
- Journal of clinical oncology : official journal…
1542 Background: High-grade gliomas (HGG) PTS progressing after surgery, radiation therapy and chemotherapy with Temozolomide have a very short survival. No particular form of therapy has been shown… Expand
Aggressive non-Hodgkin’s lymphoma – long-term survival for all patients?
Aggressive non-Hodgkin’s lymphoma (NHL) comprises a clinically and biologically heterogeneous group of neoplasms, of which diffuse large B-cell lymphoma (DLBCL) is the most common. The treatment goal… Expand
The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011
ABSTRACT Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. Methods: This was a retrospective cohort… Expand
Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer.
- E. D. Saad, P. T. Reis, +4 authors R. Gansl
- Psychology, Medicine
- Revista da Associacao Medica Brasileira
OBJECTIVE We and others have previously suggested that pretreatment levels of CA 19-9 correlate with overall survival (OS) among patients with advanced pancreatic cancer treated with gemcitabine. We… Expand
PSA decline does not correlate with overall survival in clinical trials with docetaxel for androgen independent prostate cancer (AIPC)
4673 Background: Since uncontrolled trials have shown an association between a decline in PSA levels of 50% or greater and survival, some investigators advocate that the rate of PSA decline in a ph...